Drug Trial Radar · NCT05830045
A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
180
Planned (sponsor's estimate)
Start
May 19, 2023
Primary completion
Apr 30, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
QLP2117Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT)Time frame: 21days
- Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0Time frame: up to 96 weeks
- Objective Response Rate for phase 1bTime frame: up to 96 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.